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ABSTRACT
Objectives: Despite sleep disturbances being a central
complaint in patients with chronic fatigue syndrome
(CFS), evidence of objective sleep abnormalities from
over 30 studies is inconsistent. The present study
aimed to identify whether sleep-specific phenotypes
exist in CFS and explore objective characteristics that
could differentiate phenotypes, while also being
relevant to routine clinical practice.
Design: A cross-sectional, single-site study.
Setting: A fatigue clinic in the Netherlands.
Participants: A consecutive series of 343 patients
meeting the criteria for CFS, according to the Fukuda
definition.
Measures: Patients underwent a single night of
polysomnography (all-night recording of EEG,
electromyography, electrooculography, ECG and
respiration) that was hand-scored by a researcher blind
to diagnosis and patient history.
Results: Of the 343 patients, 104 (30.3%) were
identified with a Primary Sleep Disorder explaining
their diagnosis. A hierarchical cluster analysis on the
remaining 239 patients resulted in four sleep
phenotypes being identified at saturation. Of the 239
patients, 89.1% met quantitative criteria for at least one
objective sleep problem. A one-way analysis of
variance confirmed distinct sleep profiles for each
sleep phenotype. Relatively longer sleep onset
latencies, longer Rapid Eye Movement (REM) latencies
and smaller percentages of both stage 2 and REM
characterised the first phenotype. The second
phenotype was characterised by more frequent
arousals per hour. The third phenotype was
characterised by a longer Total Sleep Time, shorter
REM Latencies, and a higher percentage of REM and
lower percentage of wake time. The final phenotype
had the shortest Total Sleep Time and the highest
percentage of wake time and wake after sleep onset.
Conclusions: The results highlight the need to
routinely screen for Primary Sleep Disorders in clinical
practice and tailor sleep interventions, based on
phenotype, to patients presenting with CFS. The results
are discussed in terms of matching patients’ self-
reported sleep to these phenotypes in clinical practice.
INTRODUCTION
Chronic fatigue syndrome (CFS), as deﬁned
by the international consensus deﬁnition,1 is
a condition characterised by profound
fatigue, of deﬁnite onset, which has
persisted for at least 6 months, and causes
substantial disruption to the individual’s
ARTICLE SUMMARY
Article focus
▪ Despite 85–90% of patients with chronic fatigue
syndrome (CFS) reporting unrefreshing sleep,
previous research has been unable to reliably
identify specific irregularities in objective sleep.
▪ To explore the possibility that sleep problems in
this population are not homogeneous and that
several sleep-specific phenotypes exist in this
population which are amenable to different treat-
ment approaches.
Key messages
▪ Over 30% of individuals with CFS met the diag-
nostic criteria for Sleep Apnoea or Periodic Limb
Movement (PLM) Disorder that could explain
their current diagnosis.
▪ The sleep in those with CFS, without Sleep
Apnoea or PLM Disorder, centred around four
specific sleep-disturbed phenotypes, with 89.1%
demonstrating quantitative criteria for insomnia
or hypersomnolence.
▪ Each sleep-phenotype in CFS comprised object-
ive characteristics that could be assessed and
differentiated using patient’s self-reports in
primary care.
Strengths and limitations of this study
▪ This is the first study to suggest, and identify,
specific sleep-phenotypes in a large sample of
patients with CFS.
▪ The objective findings can be easily translated
and applied in routine primary care.
▪ A limitation is the use of a single-night of
polysomnography.
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daily functioning. In addition to fatigue, at least four
other key symptoms are required to fulﬁl diagnostic cri-
teria, including muscle and joint pain, headache, cogni-
tive dysfunction and unrefreshing sleep. Thus deﬁned,
CFS affects between 0.23% and 2.6% of the adult popu-
lation.2–4 There are several theories as to the pathogen-
esis of CFS. However, it is most likely that the
development and maintenance of CFS are multifactorial.
Predisposing factors include a general propensity to
both emotional and physical distress, a history of abuse,
being more than usually physically active and being per-
fectionist.5–8 Precipitating events include viruses such as
glandular fever and major life events.9 10 Several factors
appear to be involved in the maintenance of symptoms.
Physiologically, evidence suggests dysregulation of the
hypothalamic pituitary adrenal (HPA) axis, increased
cytokine production and HPA responsiveness to cyto-
kines,11 12 hypersensitivity in the central nervous system
(ie, central sensitisation)13 14 and autonomic dysfunc-
tion.15 16 Two studies also highlight the importance of
illness beliefs and behaviours.17 18 Individuals who adopt
all or nothing coping styles in response to symptoms (ie,
push on through until they crash out) and attribute
broad ranges of everyday symptoms to their illness are
more likely to develop CFS postvirally. In sum, research
suggests that in CFS multiple processes in distinct
domains, such as physiology, illness beliefs, inconsistent
activity, sleep disturbance, medical uncertainty and lack
of guidance, can interact to maintain or exacerbate
symptoms.19
As aforementioned, unrefreshing sleep is one key diag-
nostic characteristic of CFS.1 It is also one of the most
common symptom complaints,20 21 with 87–95% of
patients reporting sleep difﬁculties (Gotts ZM, unpub-
lished PhD thesis) that do not improve over the course of
the illness.22 Where the purpose of sleep is the subject of
intense debate, its importance to human health and well-
being is undeniable. Examinations of individuals deprived
of or restricted from sleep consistently demonstrate dete-
riorations in mood, cognition and performance.23 The
purpose of each different sleep stage is also unclear,
although it is generally agreed that the lighter stages of
sleep (stage 1 sleep and stage 2 sleep) afford transitions
between wakefulness and sleep and then between slow
wave sleep (SWS) and Rapid Eye Movement sleep (REM).
SWS and REM are believed to confer recuperative, restora-
tive and learning properties for the individual (eg, the
secretion of growth hormone, consolidation of
memory).24 25 Therefore, the proportion of each sleep
stage and timing of entry into each sleep stage, SWS and
REM in particular, are important for the long-term main-
tenance of human physical and mental health.
Symptoms such as unrefreshing sleep may not only be
markers of CFS; they may also serve to maintain it. For
instance, there may be reciprocal links between sleep
quality, sleep-wake regulation and fatigue. There is evi-
dence of this. For instance, studies have shown that
adopting activity and sleep management strategies
improves HPA axis functioning as measured by cortisol
levels.26 This suggests that further investigation of sleep
disturbance of CFS is of more than academic import-
ance but may highlight new avenues for intervention.
From a clinical perspective, it is also important to study
sleep more thoroughly in CFS as it may highlight some
areas of diagnostic ambiguity. For instance, previous
studies have shown that sleep disorders (notably
obstructive-sleep apnoea) are occasionally identiﬁed
during polysomnographic (PSG) assessments with CFS
patient cohorts.27–30
Although over 30 PSG studies on individuals with CFS
exist, conclusive statements about the type of sleep abnor-
malities in this population are difﬁcult. Few studies report
a full characterisation of both sleep continuity (the timing,
efﬁciency and amount of sleep obtained) and sleep archi-
tecture (amount of each sleep or wake stage and the
timing of transitions to each sleep stage), with some
studies providing no PSG data at all.27 31–35 Moreover,
reporting practices differ widely, making interpretation
and comparisons difﬁcult (eg, studies report the percent-
age of each sleep and wake stage as an index of Sleep
Period Time, Total Sleep Time (TST) or even Time in
Bed),29 30 36–43 while others report the number of minutes
spent in each stage.44–48 What can be concluded from pre-
vious PSG studies is that, in each study, deviations from
‘normal sleep’ exist, but there is no consistent pattern. For
example, where two studies44 45 report poor sleep efﬁcien-
cies and ‘normal range’ REM latencies, others36 37 45
found ‘normal range’ sleep efﬁciencies and short REM
latencies and yet others still report a normal sleep efﬁ-
ciency and a long-REM latency (REML)41 or poor sleep
efﬁciency and long-REM latencies.48 Moreover, the picture
remains unclear after controlling for the severity of
patients’ self-reported sleep complaints.49 50 Although dif-
ferences in protocol, deﬁnitional criteria and reporting
criteria may, to some extent, explain these differences, an
alternative explanation is that sleep difﬁculties in indivi-
duals with CFS are not homogeneous and various sleep
phenotypes exist in this population.
To clarify the speciﬁc characterisation of sleep in CFS,
the current study examined PSG data for a single night
of sleep in a large group of CFS patients, to determine
whether speciﬁc sleep disturbances exist in this group,
and if so, whether they are consistent across all patients.
METHOD
A cross-sectional, single-site observational study was
undertaken on a consecutive series of 343 patients
(mean age 37.21+12.42 years; 72 men and 271 women)
referred for a single-night PSG study at a fatigue clinic in
the Netherlands. The referral criteria for PSG investiga-
tion were that the patient (1) met diagnostic criteria for
CFS according to the Fukuda deﬁnition, (2) they were
drug-free for at least 2 weeks prior to the overnight study
and (3) their symptoms could not be explained by a
physical or psychological illness (eg, anxiety or
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depression). Patients gave informed consent to take part
in the study and were then interviewed and medically
screened for the referral criteria by a registered phys-
ician and a registered psychiatrist. The Ethics
Committee for the School of Life Sciences at
Northumbria University had approved the study.
Patients arrived at the clinic 2 h before normal
bedtime for electrode placement and biocalibration.
The PSG montage comprised a standard 10/20 (ie,
F4-M1, C4-M1, O2-M1 and Cz with backups at F3-M2,
C3-M2, O1-M2 and Fpz). Additional channels were
used for electro-oculography (EOG; E1 and E2 refer-
enced to M2), electromyography (chin and anterior tibi-
alis placements), ECG, and airﬂow, effort, body position
and oximetry (via a pulse oximeter). Filter settings were
set to the American Academy of Sleep Medicine51 guide-
lines (eg, low 0.3 Hz/high 35 Hz for EEG and EOG)
with a sampling rate of 500 Hz. Impedances were main-
tained below 5 kΩ. Participants slept in the laboratory
overnight and were allowed to retire to bed when they
wished and left to naturally wake in the morning.
Scoring was conducted manually by a registered
BRPT-certiﬁed technician at 30 s epochs, according to
the AASM guidelines. The scorer was blind to the aims
of the study. The mean recording period was just over
8 h (508.5±63.11 min). Descriptions of all sleep variables
are detailed in table 1.
Analytic strategy
A hierarchical cluster analysis was used to determine the
number of phenotypes within the present sample after
excluding those with Sleep Apnoea or Periodic Limb
Movement (PLM) Disorder. Cluster analysis is a
data-reduction technique that examines patterns among
a set of variables to form homogeneous groups. The
Euclidean squared distance measure of similarity
method was chosen for the cluster analysis as it uses the
progressive distance between variables to form the
groups and does not rely upon standardised data. As
cluster analysis can be affected by multicollinearity, a
correlation matrix was used to exclude variables that
were highly correlated with one another. A one-way ana-
lysis of variance (ANOVA) was used to examine which of
the sleep variables differentiated the phenotypes.
RESULTS
An initial examination of the Apnoea Hypopnoea Index
(AHI) and PLM indices indicated that 104 (43 men and
61 women) of the original 343 referrals (30.3%) met the
AASM criteria for either sleep apnoea (AHI≥15; n=101)
or a PLM disorder (PLMs≥5; n=17) (14 participants met
the criteria for both disorders). The overall sleep proﬁle
of the remaining 239 patients (mean age 34.4±11.84;
210 women and 29 men) was highly variable, indicating
the presence of phenotypes (ﬁgure 1).
A hierarchical cluster analysis, using Ward’s method,
was undertaken to determine the number of groups
(clusters) within the remaining 239 patients. Prior to the
cluster analysis, a correlation matrix was examined to
avoid multicollinearity inﬂuencing the cluster model.
On this basis, four variables were excluded (height,
weight, sleep efﬁciency and number of spontaneous
arousals per hour) for having correlation coefﬁcients
with one or more variables above r=0.8. The ﬁnal group-
ing variables included in the cluster analysis were: age,
sex, body mass index (BMI), AHI’s, PLM index, Number
of Awakenings, Number of Arousals per hour, TST, Sleep
Latency (SL), Wake After Sleep Onset (WASO), percent-
age of %N1 (stage 1 sleep) of TST, %N2 (stage 2 sleep)
of TST, %N3 (SWS) of TST, %WAKE of TST, %REM of
TST and REML. The Euclidean squared distance
measure of similarity was used to group patients accord-
ing to the included variables.
There were six clustering iterations overall (going
from 8 to 2 clusters). The fourth iteration was chosen as
the saturation point as it was the point where the
agglomeration schedule and dendrogram had the
highest reduction in the number of groupings (from six
groups to four groups=reduction of 33%) while retain-
ing at least 5% of the total sample size in each group
Table 1 Description of sleep variables
Total sleep time (min) Amount of time asleep
Sleep Onset Latency (min) Length of time from lights out to first episode of stage 2 sleep
Wake After Sleep Onset (min) Number of minutes of recorded wake following first episode of stage 2 sleep
Number of awakenings (over TSP) Number of wake bouts following first episode of stage 2 sleep
Number of arousals Number of arousals over the entire sleep period
REM Latency Length of time to first REM stage
AHI Index Number of apnoea or hypopnia events per hour of sleep
Percentage of N1 (of TST) Percentage of recorded stage 1 sleep over the total time asleep
Percentage of N2 (of TST) Percentage of recorded stage 2 sleep over the total time asleep
Percentage of N3 (of TST) Percentage of recorded slow wave sleep over the total time asleep
Percentage of REM (of TST) Percentage of recorded REM sleep over the total time asleep
Percentage of WAKE (of TSP) Percentage of recorded wake over the total sleep period (ie, how long they
were awake following first episode of stage 2 sleep)
REM, rapid eye movement; TSP, total sleep period; TST, total sleep time.
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(ie, n≥11). This latter rule was chosen to afford sufﬁ-
cient power for inferential data analysis to occur.
A one-way ANOVA was undertaken on the four groups
to determine which sleep variables signiﬁcantly differen-
tiated the groups. There were no overall differences
between the groups on age (p=0.12) or BMI (p=0.48).
On inspection of the sex frequencies in each group,
there was a higher ratio of men to women in the ﬁrst
group compared with the other three groups. However,
as two groups contained less than ﬁve men, this could
not be tested statistically. In relation to the polysomno-
graphy variables, there were no group differences in the
number of arousals per hour or AHI index scores (PLMs
were not included as less than 10% of the total sample
had a PLM index), but signiﬁcant differences were
observed on all the other sleep variables (table 2).
First phenotype
The ﬁrst phenotype comprised 14 patients with the
longest Sleep Onset and REMLs and the highest per-
centage of SWS. Moreover, this group had the lowest
percentages of both stage 2 sleep and REM sleep.
Statistically; this phenotype differed from the other
three groups in terms of longer Sleep Onset and REMLs
and a lower percentage of REM.
Second phenotype
The second phenotype comprised 55 patients with the
highest percentage of stage 2 sleep and the highest
number of arousals per hour, although neither of these
variables statistically separated them from the other
three phenotypes.
Third phenotype
The third phenotype comprised 146 patients with the
highest TST and percentage of REM. Additionally, this
group demonstrated the shortest Sleep Onset and
REMLs, lowest WASO and percentages of wake time and
stage 1 sleep, and the lowest number of awakenings.
Statistically, TST, percentage wake and WASO differen-
tiated this phenotype from each of the others.
Fourth phenotype
The fourth phenotype comprised 24 patients who
demonstrated the highest WASO, percentages of wake
and stage 1 sleep, and the highest number of awaken-
ings. This group was also the lowest in terms of TST,
number of arousals per hour and percentage of SWS.
Statistically, only WASO and percentage of wake differen-
tiated this group from each of the other groups.
DISCUSSION
The aim of the study was to determine whether speciﬁc
sleep phenotypes existed in patients with CFS. A large
consecutive series of patients, meeting the criteria for
CFS, underwent a single night of polysomnography to
determine the presence or absence of distinct sleep phe-
notypes. The ﬁrst ﬁnding, over 30% of individuals
meeting diagnostic criteria for CFS, also demonstrated
that a Primary Sleep Disorder (PSD; sleep apnoea or
Figure 1 Study overview.
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Table 2 Characteristics of sample of individuals with CFS
Grouped variable clusters Group 1 (N=14) Group 2 (N=55) Group 3 (N=146) Group 4 (N=24) F p Value
Demographics
Age 35.79 (12.39) 37.29 (12.72) 32.99 (10.82) 35.54 (14.49) 1.95 ns
Sex 5 Males (35.71%) 10 Males (17.65%) 14 Males (9.59%) 1 Male (4.17%) * *
BMI 24.86 (5.68) 23.85 (4.63) 23.41 (4.03) 22.81 (3.86) 0.82 ns
Sleep Variables
Total Sleep Time (min) 270.95 (41.85)ab 387.03 (46.1)acd 473.21 (45.82)bce 264.15 (74.43)de 188.07 p< .001
Sleep Onset Latency (min) 107.79 (42.09)abc 30.97 (29.13)ad 19.17 (14.71)bd 28.94 (27.54)c 67.26 p< .001
Wake After Sleep Onset (min) 75.79 (39.35)ab 82.12 (45.25)cd 35.45 (25.39)ace 180.2 (58.48)bde 119.74 p< .001
Number of Awakenings (over TSP) 15.21 (8.06) 14.75 (11.62)ab 9.54 (5.85)a 16.96 (9.26)b 10.52 p< .001
Number of Arousals 3.57 (9.21) 10.91 (23.01) 6.2 (15.26) 1.38 (4.13) 2.24 ns
REM latency 173.22 (55.03)abc 57.71 (34.31)ad 47.01 (28.22)be 84.46 (48.21)cde 63 p< .001
AHI index 3.43 (3.46) 4.58 (4.39) 4.73 (4.04) 3.54 (4.19 0.92 ns
Percentage of N1 (of TST) 21.84 (13.36)a 14.35 (9.14)b 12.55 (7.37)ac 24.22 (14.82)bc 14.15 p< .001
Percentage of N2 (of TST) 27.57 (13.15)ab 38.82 (12.36)a 38.44 (12.14)b 36.95 (13.66) 3.46 p< .02
Percentage of N3 (of TST) 44.46 (20.45)abc 31.07 (11.05)a 31.78 (12.41)b 29.28 (16.42)c 4.64 p< .004
Percentage of REM (of TST) 6.11 (4.58)abc 15.16 (5.47)ad 17.19 (5.57)be 9.65 (6.35)cde 26.46 p< .001
Percentage of WAKE (of TSP) 60.32 (21.09)abc 25.75 (11.61)ade 11.03 (6.16)bdf 75.26 (22.92)cef 271.62 p< .001
Note: Letters sharing the same subscript are significantly different.
*Statistical tests of between-group sex differences could not be performed due to the small number of men in each group.
AHI, Apnoea Hypopnoea Index; BMI, body mass index; CFS, chronic fatigue syndrome; TSP, total sleep period; TST, total sleep time; REM, rapid eye movement.
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PLMD) is important and underscores the need to assess
for PSDs in CFS populations. As the recommended treat-
ment strategies for some PSDs differ considerably from
those for CFS (eg, Continuous Positive Airway Pressure
for apnoea vs sleep management strategies in CFS), it is
important to direct the individual to, or adjunct, appro-
priate care pathways as soon as possible. This ﬁnding
also questions the ability to differentiate fatigue asso-
ciated with sleep apnoea or PLMD from that associated
with CFS. Here, family members and/or carers may be
helpful for diagnosis sensitivity as they are likely to be
aware of nocturnal breathing disturbances (ie, heavy
snoring, gasping or pauses in breathing).
The overall PSG results (after excluding sleep apnoea
and PLMD) conﬁrm objective sleep difﬁculties in
patients with CFS. When the percentages of each sleep
stage in ‘normal’ adult sleepers (ie, <5% wake, between
2% and 5% stage 1, between 45% and 55% stage 2,
between 13% and 23% SWS and between 20% and 25%
REM52) are compared with those in the present sample,
it is seen that this group falls outside the range for all
these variables. The present sample is spending more
time awake and in the lighter stages of sleep (stages 1
and 2 sleep), and less time in the deeper sleep stages of
sleep (ie, stage 2 sleep and SWS) and in REM. Further,
using the quantitative benchmarks of sleep disturbance
outlined by Edinger et al,53 it can be seen that where
sleep efﬁciency and SLs appear to be on the cusp of
‘normal’ sleep in the present sample (85% sleep efﬁ-
ciency is considered normal and SL of >30 denotes a
sleep problem), WASO appears to be almost twice as
long as is considered problematic (>30 min tends to
denote a sleep problem). Together, these ﬁndings indi-
cate that sleep is an objectively veriﬁable problem for
patients with CFS that should be addressed clinically.
The cluster analysis identiﬁed, at saturation, four sleep
phenotypes. The dendrogram identiﬁed two groups par-
tially related (ie, groups 1 and 4) and two that were
largely independent (ie, groups 2 and 3). This conﬁgur-
ation was conﬁrmed by ANOVA showing statistically sig-
niﬁcant differences in sleep continuity and architecture
variables between the groups. That said, where statistical
signiﬁcance and relative characterisation (eg, highest in
variable WX and Y and lowest in variable Z) are import-
ant in understanding between-group differences, the
more salient question is whether these four groups are
clinically relevant in terms of speciﬁc sleep treatments in
patients with CFS. The use of different pharmacological
agents (benzodiazepines, z-hypnotics or stimulants) or
therapeutic interventions (ie, Cognitive Behavioural
Therapy for Insomnia or behavioural modiﬁcation strat-
egies) has been shown to have differential effects on spe-
ciﬁc aspects of sleep continuity and architecture. For
example, zolpidem appears to have a better impact on
the number of awakenings and perceived quality of sleep
compared with nitrazepam, and lormetazapam appears
to be better in reducing SLs than zoplicone.54 As such,
tailoring treatment options to the sleep problems pre-
senting in this population is likely to be more effective
(table 3).
Another consideration, albeit related, is the presence
within the ﬁnal sample of PSDs for which PSG is either
not routinely recommended or where, as stand-alone, it
is insufﬁcient for a deﬁnitive diagnosis.51 Most relevant
to the present sample are insomnia disorder and hyper-
somnolence disorders. Interestingly, groups 1 and 4
appear to be characterised by insomnia-like symptoms
(ie, difﬁculties initiating sleep or maintaining sleep),
whereas groups 2 and 3 appear to share overlapping
characteristics with disorders characterised by poor sleep
Table 3 Characteristics (statistical and phenomenological) of patients with CFS
Sleep
phenotype Central differential features Associated diagnostic features
How this may present
subjectively
1 Long Sleep Onset Latency, Long
REM Latency, High amounts of
Slow Wave Sleep and low
amounts of REM
Low amounts of stage 2 sleep Problems in getting off to sleep but
when asleep few awakenings. The
sleep that is obtained is of normal
quality
2 High number of arousals per hour
and high amounts of stage 2 sleep
No difficulties in getting off to sleep
and few awakenings but feelings or
evidence of a ‘restless’ night sleep
3 High Total Sleep Time, low
amounts of time awake during
the night and low number of
wake periods during the night
High amounts of REM Sleep, Short
Sleep Onset Latency, Low number of
Awakenings, Short REM Latencies
and low amounts of stage 1 sleep
No difficulties in getting off to sleep
and few awakenings but feelings of
being unrefreshed on waking
despite a significant amount of
time in bed asleep
4 Highest number of wake periods
during the night and highest
amounts of time awake during
the night
Low Total Sleep Time, Low number
of arousals per hour during the night
and Low amounts of Slow Wave
Sleep
Short sleep duration and although
no difficulties getting off to sleep
lots of awakenings for significant
periods of time. Also increased
feelings of daytime sleepiness
CFS,chronic fatigue syndrome; REM,Rapid Eye Movement.
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quality (table 2). In relation to group 3, there is some
overlap with hypersomnolence disorders (the term
hypersomnolence will replace hypersomnia under the
DSM-5) as 14 patients (9.59%) slept for 9 h or longer
and eight patients (5.48%) demonstrated the main poly-
somnographically deﬁned symptom of narcolepsy (ie, an
REML of less than 15 min). For group 2, there is no
obvious overlap with a speciﬁc DSM-5-deﬁned sleep dis-
order, although as stage 2 sleep has been associated with
hormonal and autonomic regulation,55 increased
amounts are likely to relate to both higher levels of auto-
nomic and cortical arousal inhibiting deep sleep. As
such, a PSG study with adjunct sleep history interviews,
sleep diaries, actigraphy and/or a Multiple Sleep
Latency Test or Maintenance of Wakefulness test would
be valuable tools in determining whether these groups
share all the diagnostic features of each PSD.
The ﬁndings from the present study should be viewed
with the limitations in mind. There was no control
group to determine the extent to which the four pheno-
types exist in the general population. That said, with
6–10% of the population meeting the diagnostic criteria
for insomnia56 and 5% meeting the diagnostic criteria
for hypersomnia,57 the present data do not reﬂect this
with 213 of the 239 (89.1%) participants, without
apnoea or PLMS, meeting at least one quantitative cri-
terion for insomnia or hypersomnia. It could also be
argued that a single night of polysomnography may not
be enough to capture the sleep of patients with CFS due
to the ﬁrst-night-effect.44 The ﬁrst-night-effect is a com-
monly observed response to the ﬁrst night of sleeping in
an unusual environment, such as a sleep laboratory,
whereby aspects of sleep can be affected. That said,
where Le Bon and colleagues demonstrated signiﬁcant
differences between nights 1 and 2 in a cohort of indivi-
duals with CFS, these differences were not largely
evident in the sleep architecture and many differences
in the sleep continuity variables disappeared after those
with psychiatric illnesses were excluded from the ana-
lysis. Interestingly, over 25% of Le Bon et al’s44 sample
also demonstrated an ‘inverse ﬁrst-night-effect’ whereby
they slept better on the ﬁrst night compared with the
second night. This issue of the ﬁrst-night-effect in CFS is
further complicated by other studies which have shown
no such effect in this population.30 It is very likely that
inconsistencies in the ﬁrst-night-effect reﬂect typical
night-to-night variability58–60 in addition to situation-
speciﬁc factors, such as acclimating to a new environ-
ment, relating to PSG on the ﬁrst and second nights.
What would be ideal, albeit expensive, is a PSG study
over several nights (eg, at least 14 continuous nights are
suggested for insomnia61) to ensure that these issues are
accounted for. That said, what may be more practical is
to determine how information from the present study
can inform, in conjunction with other assessments,
actual clinical practice. One suggestion is that, ideally
after ruling out PSDs, individuals should be interviewed
about their sleep (usually over the last month) and
provided a sleep diary. This information would provide a
subjective account that could be matched to the four
phenotypes (as in table 3) to inform treatment.
Overall, the results suggest a signiﬁcant overlap
between CFS and a variety of symptoms of sleep disturb-
ance. One night of PSG is sufﬁcient to tease apart, and
exclude, those with apnoea and PLM disorders from
four other distinct sleep phenotypes in patients with
CFS. Interestingly, these four phenotypes tend to mirror
symptoms related to sleep quality and quantity that are
amenable to different treatment strategies. As such, clini-
cians tailoring sleep-based interventions for patients with
CFS should be mindful of these phenotypes.
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